We are live on ! Find out more
RCUS icon

Arcus Biosciences
RCUS

131 hedge funds and large institutions have $1.68B invested in Arcus Biosciences in 2021 Q3 according to their latest regulatory filings, with 17 funds opening new positions, 36 increasing their positions, 51 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

253% more call options, than puts

Call options by funds: $4.84M | Put options by funds: $1.37M

50% more funds holding in top 10

Funds holding in top 10: 6 → 9 (+3)

36% more capital invested

Capital invested by funds: $1.24B → $1.68B (+$445M)

13% more first-time investments, than exits

New positions opened: 17 | Existing positions closed: 15

4% more ownership

Funds ownership: 63.62% → 67.62% (+4%)

1% more funds holding

Funds holding: 130 → 131 (+1)

29% less repeat investments, than reductions

Existing positions increased: 36 | Existing positions reduced: 51

Holders
131
Holders Change
+1
Holders Change %
+0.77%
% of All Funds
2.29%
Holding in Top 10
9
Holding in Top 10 Change
+3
Holding in Top 10 Change %
+50%
% of All Funds
0.16%
New
17
Increased
36
Reduced
51
Closed
15
Calls
$4.84M
Puts
$1.37M
Net Calls
+$3.47M
Net Calls Change
+$8.16M

Top Buyers

1
EC
EcoR1 Capital
California
+$55.6M
2
Franklin Resources
Franklin Resources
California
+$18.1M
3
BNP Paribas Asset Management
BNP Paribas Asset Management
France
+$14.7M
4
BCPEMI
Bain Capital Public Equity Management II
Massachusetts
+$14.2M
5
BI
BVF Inc
California
+$13.4M

Top Sellers

1
AI
Alphabet Inc
California
-$16M
2
Goldman Sachs
Goldman Sachs
New York
-$11.1M
3
State Street
State Street
Massachusetts
-$11M
4
Renaissance Technologies
Renaissance Technologies
New York
-$7.57M
5
D.E. Shaw & Co
D.E. Shaw & Co
New York
-$5.04M
Name Holding Trade Value Shares
Change 		Change in
Stake
Vontobel Holding
101
Vontobel Holding
Switzerland
$349K – – –
PCA
102
Personal Capital Advisors
California
$328K – – –
VEA
103
Virtus ETF Advisers
New York
$302K -$13.9K -447 -5%
DT
104
Diversified Trust
Tennessee
$294K – – –
ACM
105
Anfield Capital Management
California
$275K – – –
TRCT
106
Tower Research Capital (TRC)
New York
$263K +$90.9K +2,922 +63%
Victory Capital Management
107
Victory Capital Management
Texas
$254K -$1.98M -63,577 -90%
E
108
Ergoteles
New York
$230K +$205K +6,600 New
Teacher Retirement System of Texas
109
Teacher Retirement System of Texas
Texas
$219K +$196K +6,288 New
AB
110
Amalgamated Bank
New York
$207K +$184K +5,925 New
AQR Capital Management
111
AQR Capital Management
Connecticut
$205K -$989K -31,770 -84%
ProShare Advisors
112
ProShare Advisors
Maryland
$202K -$185K -5,947 -51%
Federated Hermes
113
Federated Hermes
Pennsylvania
$191K +$162K +5,217 +2,038%
Bank Julius Baer & Co
114
Bank Julius Baer & Co
Switzerland
$139K -$498K -15,993 -80%
AIP
115
Ameritas Investment Partners
Nebraska
$125K – – –
Canada Life
116
Canada Life
Manitoba, Canada
$88K – – –
QT
117
Quantbot Technologies
New York
$69K +$62.2K +2,000 New
Osaic Holdings
118
Osaic Holdings
Arizona
$44K – – –
TFO
119
Tarbox Family Office
California
$35K – – –
US Bancorp
120
US Bancorp
Minnesota
$19K +$13.8K +444 +448%
CAPTRUST Financial Advisors
121
CAPTRUST Financial Advisors
North Carolina
$12K +$405 +13 +4%
AWM
122
Activest Wealth Management
Florida
$11K – – –
Group One Trading
123
Group One Trading
Illinois
$8K +$7.1K +228 New
CG
124
Cutler Group
California
$6K -$18.7K -600 -75%
TWA
125
TCI Wealth Advisors
Arizona
$4K +$3.21K +103 New
2 3 4
5
6

RCUS Hedge Fund Activity: Q3 2021 in Review

131 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Arcus Biosciences (RCUS) for Q3 2021, worth a combined $1.68B — up 36% from $1.24B a quarter earlier.

Buyers outnumbered sellers: 17 funds opened new RCUS positions and 15 closed out — a net gain of 2 holders — while 36 added to existing stakes and 51 trimmed.

The largest buyer was EcoR1 Capital, adding an estimated $55.6M. The largest seller was Alphabet Inc, cutting an estimated $16M.

  • 131 institutional investors held Arcus Biosciences (RCUS) as of Q3 2021, up from 130 in Q2 2021.
  • Funds reported $1.68B of Arcus Biosciences stock for Q3 2021, up 36% quarter-over-quarter.
  • 17 funds opened new Arcus Biosciences positions in Q3 2021 and 15 closed out, a net change of +2 holders.
  • The largest Arcus Biosciences buyer in Q3 2021 was EcoR1 Capital, an estimated $55.6M added.
  • The largest Arcus Biosciences seller in Q3 2021 was Alphabet Inc, an estimated $16M sold.

Based on aggregated 13F filings for Q3 2021.